Differences in clinico-pathological characteristics and outcomes between proteinase 3-ANCA positivity and myeloperoxidase-ANCA positivity in lupus nephritis

Abstract

Background

Owing to the low prevalence of anti-neutrophil cytoplasmic antibodies (ANCA) in lupus nephritis (LN), there is no study about the differences between proteinase 3 (PR3)-ANCA positivity and myeloperoxidase (MPO)-ANCA positivity in LN until now.

Methods

Here we perform a retrospective study to determine whether there are differences in clinic-pathological characteristics and renal outcomes between PR3-ANCA-positive LN patients and MPO-ANCA-positive LN patients.

Results

A total of 26 (27.4%) PR3-ANCA-positive LN patients and 69 (72.6%) MPO-ANCA-positive LN patients (p < 0.001) were eligible for this study. Compared with PR3-ANCA-positive LN patients, MPO-ANCA-positive LN patients had significantly higher levels of serum creatinine (109.6 µmol/l vs. 74.3 µmol/l, p = 0.02), lower titers of antinuclear antibodies (ANA) (128 vs. 256, p = 0.01), and higher serum concentrations of C3 and C4 (0.54 g/l vs. 0.36 g/l, p = 0.002; 0.12 g/l vs. 0.06 g/l, p < 0.001; respectively). Furthermore, the MPO-ANCA-positive group had higher scores for chronicity index (p = 0.007), including interstitial fibrosis (p = 0.001) and tubular atrophy (p = 0.03) on biopsy specimens. The renal survival rates for MPO-ANCA-positive LN patients were 94.1% at 1 year, 83.2% at 5 years and 79.6% at 10 years; these values were worse when compared with those of the PR3-ANCA-positive group, which were 100%, 100% and 100%, respectively.

Conclusion

MPO-ANCA-positive LN patients had more severely impaired baseline renal function and less active lupus serology. More severely chronic pathological changes, including interstitial fibrosis and tubular atrophy on renal specimens, occurred in MPO-ANCA-positive LN patients. We found that MPO-ANCA-positive LN patients had worse renal outcomes.

Keywords

Lupus nephritis MPO-ANCA PR3-ANCA clinic-pathological characteristics renal outcomes

Get full access to this article

View all access options for this article.

References

Jarrot

Chiche

Hervier

, et al. Systemic lupus erythematosus and antineutrophil cytoplasmic antibody-associated vasculitis overlap syndrome in patients with biopsy-proven glomerulonephritis. Medicine 2016; 95: e3748.

Lech

Anders

H-J

. The pathogenesis of lupus nephritis. J Am Soc Nephrol 2013; 24: 1357–1366.

Zhou

Liang

, et al. Treatment and clinicopathological characteristics of lupus nephritis with anti-neutrophil cytoplasmic antibody positivity: A case-control study. BMJ Open 2017; 7: e015668.

Turner-Stokes

Wilson

Morreale

, et al. Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int 2017; 92: 1223–1231.

Wang

Huang

Cai

, et al. Clinicopathologic characteristics and outcomes of lupus nephritis with antineutrophil cytoplasmic antibody: A retrospective study. Medicine 2016; 95: 2580.

Yang

Liang

Zhang

, et al. Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis. Lupus 2015; 24: 1468–1478.

Jennette

Falk

. B cell-mediated pathogenesis of ANCA-mediated vasculitis. Semin Immunopathol 2014; 36: 327–338.

Jennette

Falk

. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Nephrol 2014; 10: 463–473.

Hilhorst

Wilde

Van Paassen

, et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: A 30-year follow-up study. Nephrol Dial Trans 2013; 28: 373–379.

10.

Bajema

Hagen

Hansen

, et al. The renal histopathology in systemic vasculitis: An international survey study of inter- and intra-observer agreement. Nephrol Dial Trans 1996; 11: 1989–1995.

11.

Hilhorst

Van Paassen

Tervaert

, et al. Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis. J Am Soc Nephrol 2015; 26: 2314–2327.

12.

Franssen

Stegeman

Oost-Kort

, et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J Am Soc Nephrol 1998; 9: 1915–1923.

13.

Hauer

Bajema

Van Houwelingen

, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002; 61: 80–89.

14.

Rihova

Jancova

Merta

, et al. Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney Blood Press R 2005; 28: 144–152.

15.

De Lind van Wijngaarden

Hauer

Wolterbeek

, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006; 17: 2264–2274.

16.

De Joode

Sanders

Stegeman

. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013; 8: 1709–1717.

17.

Sen

Isenberg

. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus 2003; 12: 651–658.

18.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

19.

Weening

D D'agati

Schwartz

, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521–530.

20.

Austin

Boumpas

Vaughan

, et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45: 544–550.

21.

Austin

Muenz

Joyce

, et al. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689–695.

22.

Appel

Pirani

D'Agati

. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4: 1499–1515.

23.

Hsieh

Chang

Brandt

, et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 2011; 63: 865–874.

24.

Sethi

Haas

Markowitz

, et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. J Am Soc Nephrol 2016; 27: 1278–1287.

25.

Levey

Stevens

Schmid

, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.

26.

Bombardier

Gladman

Urowitz

, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630–640.

27.

Korbet

Lewis

Schwartz

, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35: 904–914.

28.

Fujimoto

Watts

Kobayashi

, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology 2011; 50: 1916–1920.

29.

Chen

Zhang

, et al. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine 2008; 87: 203–209.

30.

Balafa

Kalaitzidis

Liapis

, et al. Crescentic glomerulonephritis and membranous nephropathy: A rare coexistence. Int Urol Nephro 2015; 47: 1373–1377.

31.

Hervier

Hamidou

Haroche

, et al. Systemic lupus erythematosus associated with ANCA-associated vasculitis: An overlapping syndrome?. Rheumatol Int 2012; 32: 3285–3290.

32.

Mahr

Katsahian

Varet

, et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: A cluster analysis. Ann Rheum Dis 2013; 72: 1003–1010.

33.

Franssen

Stegeman

Oostkort

, et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J Am Soc Nephrol 1998; 9: 1915–1923.

34.

Chen

Daha

Kallenberg

. The complement system in systemic autoimmune disease. J Autoimmun 2010; 34: 276–286.

35.

Schreiber

Xiao

Jennette

, et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009; 20: 289–298.

36.

Nasr

D'Agati

Park

H-R

, et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol 2008; 3: 682–690.

37.

Korbet

Schwartz

Evans

, et al. Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol 2007; 18: 244–254.

38.

Ayodele

Okpechi

Swanepoel

. Long-term renal outcome and complications in South Africans with proliferative lupus nephritis. Int Urol Nephrol 2013; 45: 1289–1300.

39.

Faurschou

Dreyer

Kamper

, et al. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res 2010; 62: 873–880.

40.

Tan

Liu

, et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kid Int 2009; 76: 307–317.

41.

Contreras

Pardo

Cely

, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005; 14: 890–895.

42.

Falk

Jennette

. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318: 1651–1657.

43.

Van Der Woude

Rasmussen

Lobatto

, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425–429.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.21 MB